InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+57.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Ingram Douglas S, Chairman & CEO. Director active across 2 companies, notably Sarepta Therapeutics, Inc.. In total, 6 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €2.5m. Activity tracked since 26 June 2021. The latest transaction was disclosed on 16 December 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Ingram Douglas S
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
7,819 shares0Common StockSEC:0001190644-25-000004:0
50,000 shares0Common StockSEC:0001193125-25-313184:0
38,396 shares@ US$20.09100.0% of flowCommon StockSEC:0001628280-25-004478:0
10,081 shares@ US$78.5711.2% of flowCommon StockSEC:0001209191-23-054441:0
Canonical exit: 1 Feb 2024 (T+90)
25,026 shares@ US$79.9447.6% of flowCommon StockSEC:0001209191-21-065246:0
Canonical exit: 15 Feb 2022 (T+90)
17,812 shares@ US$80.4032.3% of flowCommon StockSEC:0001209191-21-043582:0
6 of 6 declarations
About Ingram Douglas S
Douglas S. Ingram is the President and CEO of Sarepta Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and business development. His leadership is essential for innovation and growth at Sarepta Therapeutics, Inc.
